September 1, 2005 (Vol. 25, No. 15)


Strong Points: Topical information
Weak Points: Company focus not clear

As stated on the opening page of the Recombinomics site, “Recombinomics is committed to the study of recombination as the driver of rapid molecular evolution and the emergence of novel infectious agents.” OK, but that doesn’t say what Recombinomics does. Indeed, a good deal of the company’s focus is not apparent. What I was able to gather from poking around extensively was that it exploits recombination to create and evaluate vaccine therapies (one approach). The text at the main site is pretty lacking in content (save for the obvious concerns about bird flu), but I was able to learn quite a bit from the links to online discussion and news programs involving the founder of the site. While I’m still a little hazy on the aims here, they clearly involve evolving viruses and so, with the giant threat posed by bird flu, this site rates at least a mention.

Previous articleAnimal-Derived Agents in Disposable Systems
Next articleScience and Democracy in Europe and the United States